CoChat

Psychiatric safety of ketamine in psychopharmacology research

Open access
Perry, Edward B., Cramer, Joyce A., Cho, Hyun-Sang, Petrakis, Ismene L., Karper, Laurence P., Genovese, Angelina, O’Donnell, Elizabeth, Krystal, John H., D’Souza, D. Cyril, Yale Ketamine Study Group · 2007 · Psychopharmacology

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

RationaleA growing number of investigators are studying ketamine effects in healthy human subjects, but concerns remain about its safety as a research tool. Therefore, it is timely to revisit the safety of subanesthetic doses of ketamine in experimental psychopharmacology studies.ObjectiveTo report on the safety of laboratory studies with subanesthetic doses of ketamine in healthy humans using an existing dataset.Materials and methodsMedically healthy subjects with no personal or familial Axis I psychotic spectrum disorders were administered subanesthetic doses of ketamine by intravenous infusion in a series of clinical investigations from 1989 to 2005. The safety of ketamine administration was monitored in these subjects.ResultsFour hundred and fifty subjects received at least one dose of active ketamine. Eight hundred and thirty three active ketamine and 621 placebo infusions were administered. Ten adverse mental status events were documented in nine subjects/infusions that were deemed related to ketamine administration (2% of subjects, 1.45% of infusions). All but one adverse reaction resolved by the end of the test session. The side effects in the remaining individual were no longer clinically significant within 4 days of the test session. No residual sequelae were observed.ConclusionKetamine administration at subanesthetic doses appears to present an acceptable level of risk for carefully screened populations of healthy human subjects in the context of clinical research…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00213-007-0706-2

Cites

41 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Research works printed but not linked: 1

  1. Spitzer RL, Williams JBW, Gibbon M, First MB (1990) Structured Clinical Interview for DSM-III-R-Non-Patient Edition (SCID-NP, Version 1.0 with supplement for DSM-IV). American Psychiatric, Washington, DC

Cited by

See all 124

Metadata

Authors
Perry, E. B., Cramer, J. A., Cho, H.-S., Petrakis, I. L., Karper, L. P., Genovese, A., O’Donnell, E., Krystal, J. H., D’Souza, D. C., & Yale Ketamine Study Group
Affiliations
  • Yale University (US)
  • Yonsei University (KR)
  • VA Connecticut Healthcare System (US)
Corresponding author
Perry, Edward B.
Venue
Psychopharmacology
Published
2007-02-16
Volume
192
Issue
2
Pages
253-260
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
OpenAlex
W2039637101
Cited by
117
References
41
Citations by year
2025: 1 · 2024: 4 · 2023: 1 · 2022: 6 · 2021: 7 · 2020: 10 · 2019: 5 · 2018: 11 · 2017: 10 · 2016: 11 · 2015: 11 · 2014: 11 · 2013: 8 · 2012: 1
FWCI
0.52
Type
journal article
Language
en
Open access
Licence
Locations
  • Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
ketamine, subanesthetic doses, healthy volunteers, intravenous infusion, adverse event monitoring
MeSH terms
Adult, Aged, Mental Disorders, Clinical Trials as Topic, Dose-Response Relationship, Drug, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychopharmacology, Risk, Excitatory Amino Acid Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Psychiatric safety of ketamine in psychopharmacology research. https://app.cochat.ai/papers/10.1007/s00213-007-0706-2
The paper
Perry, E. B., Cramer, J. A., Cho, H.-S., Petrakis, I. L., Karper, L. P., Genovese, A., O’Donnell, E., Krystal, J. H., D’Souza, D. C., & Yale Ketamine Study Group. (2007). Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology. https://doi.org/10.1007/s00213-007-0706-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.